- Email: [email protected]
3FS07-6 Biological therapies for atherosclerosis
3FS07
Wednesday October 1, 2003: Featured Symposium Bridging the Decades: New Era is Open with Preclinical and Clinical Trials
183
a French-Canadian Family (R237W). These mutations reduced the in vitro autocatalytic activity of NARC-1. The mechanism of the cholesterol-reducing effect of NARC-1 is still speculative. We demonstrate for the first time that statins dose-dependently increase the mRNA levels of NARC-1. This is a new pleiotropic effect of statins. NARC-1 may constitute an important new target for drug therapy of hypercholesterolemia. 3FS07-6
Biological therapies for atherosclerosis
M. Davidson. Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL, USA Biological therapies may provide significant benefits for the treatment of atherosclerosis. Autoimmunization is the process of vaccination to develop internal antibodies to inhibit the actions of various proteins or receptors. Vaccination to inhibit plasma cholesteryl ester transfer protein (CETP) results in elevated anti-CETP antibodies and clinical trials are underway to determine if these antibodies inhibit CETP sufficiently to raise high-density lipoprotein levels. Another potential target for autoimmunization is oxidized low-density lipoprotein (LDL). Exciting new clinical studies are focusing on intravenous and oral forms of Apo-A1 mimetic to inhibit atherosclerosis in humans, while various peptides have recently been shown to enhance LDL clearance in animals. Biological therapies for use in other disease states are on the horizon for the prevention and treatment of atherosclerosis.
WEDNESDAY
XIIIth International Symposium on Atherosclerosis, September 28–October 2, 2003, Kyoto, Japan
Wednesday October 1, 2003: Featured Symposium Bridging the Decades: New Era is Open with Preclinical and Clinical Trials
183
a French-Canadian Family (R237W). These mutations reduced the in vitro autocatalytic activity of NARC-1. The mechanism of the cholesterol-reducing effect of NARC-1 is still speculative. We demonstrate for the first time that statins dose-dependently increase the mRNA levels of NARC-1. This is a new pleiotropic effect of statins. NARC-1 may constitute an important new target for drug therapy of hypercholesterolemia. 3FS07-6
Biological therapies for atherosclerosis
M. Davidson. Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL, USA Biological therapies may provide significant benefits for the treatment of atherosclerosis. Autoimmunization is the process of vaccination to develop internal antibodies to inhibit the actions of various proteins or receptors. Vaccination to inhibit plasma cholesteryl ester transfer protein (CETP) results in elevated anti-CETP antibodies and clinical trials are underway to determine if these antibodies inhibit CETP sufficiently to raise high-density lipoprotein levels. Another potential target for autoimmunization is oxidized low-density lipoprotein (LDL). Exciting new clinical studies are focusing on intravenous and oral forms of Apo-A1 mimetic to inhibit atherosclerosis in humans, while various peptides have recently been shown to enhance LDL clearance in animals. Biological therapies for use in other disease states are on the horizon for the prevention and treatment of atherosclerosis.
WEDNESDAY
XIIIth International Symposium on Atherosclerosis, September 28–October 2, 2003, Kyoto, Japan